Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
RCT (n=43) found the addition of belimumab to rituximab and cyclophosphamide was safe in patients with refractory lupus nephritis, however clinical efficacy was not improved (partial response at week 48 = 52% vs 41% for with and without belimumab, p=0.452).
Source:
Arthritis & Rheumatology